BrightPath BiotherapeuticsBrightPath Biotherapeutics Co., Ltd.4594東証グロース医薬品FY ending Mar 2025, non-consolidated, J-GAAP
It lost about ¥102464 for every ¥100 of sales at the operating level. Revenue changed +1473.6% from the prior year.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2021 | — | —× | -45.9% | —× | — |
| 2022 | — | —× | -45.5% | —× | — |
| 2023 | — | —× | -66.4% | —× | — |
| 2024 | — | —× | -79.7% | —× | — |
| 2025 | — | —× | -97.9% | —× | — |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2021 | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 |
|---|---|---|---|---|---|
| Revenue | 3 | 15 | 5 | 0 | 1 |
| Cost of revenue | 1 | 3 | 2 | 0 | 0 |
| Gross profit | 1 | 12 | 3 | 0 | 1 |
| SG&A | 1,734 | 1,488 | 1,470 | 1,155 | 1,162 |
| Operating income | -1,733 | -1,476 | -1,467 | -1,155 | -1,161 |
| Pretax income | -1,717 | -1,482 | -1,484 | -1,166 | -1,149 |
| Income tax | 2 | 2 | 2 | 2 | 2 |
| Net income attributable to owners | -1,720 | -1,484 | -1,486 | -1,168 | -1,151 |
| Operating margin | -69201.4% | -9579.7% | -27785.2% | -1604275.0% | -102464.1% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2021 | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥3.27B | ¥2.31B | ¥1.53B | ¥1.06B | ¥810.5M |
| Total assets | ¥3.75B | ¥2.77B | ¥1.7B | ¥1.23B | ¥1.12B |
| Net assets | ¥3.54B | ¥2.53B | ¥1.57B | ¥979M | ¥925M |
| Share capital | ¥6.46B | ¥6.7B | ¥362.2M | ¥650.7M | ¥1.2B |
| Property, plant and equipment | ¥48.2M | ¥24.9M | ¥0 | ¥0 | ¥0 |
| Intangible assets excluding goodwill | ¥0 | ¥0 | ¥0 | ¥0 | ¥0 |
| Current assets | ¥3.65B | ¥2.7B | ¥1.65B | ¥1.18B | ¥1.07B |
| Current liabilities | ¥156.4M | ¥184.7M | ¥76.6M | ¥191M | ¥131.7M |
| Total liabilities | ¥211.8M | ¥239.7M | ¥133.9M | ¥251.3M | ¥195.6M |
| Equity attributable to owners of parent | ¥3.51B | ¥2.51B | ¥1.55B | ¥956.1M | ¥903.4M |
| Retained earnings | -¥9.39B | -¥10.9B | -¥1.49B | -¥2.65B | -¥3.8B |
| Treasury stock | — | — | ¥0 | ¥0 | -¥2K |
EDINET (FSA Japan)
有価証券報告書－第23期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第22期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第21期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第20期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
訂正有価証券報告書－第19期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第18期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 40 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.